KN15-ABD (IL15-ABD fusion protein)

---

KINE Biotech has developed a proprietary IL15-ABD fusion protein that combines the potent immune-activating properties of interleukin-15 with an albumin-binding domain (ABD) to significantly extend its half-life and systemic exposure. This extended-duration cytokine has shown strong antitumor efficacy in multiple murine models, including orthotopic liver and pancreatic cancers, by promoting the expansion and activation of CD8+ T cells and NK cells. The IL15-ABD fusion is currently under evaluation in an investigator-initiated trial (IIT) in Taiwan for treating canine lung metastases of melanoma and osteosarcoma, offering translational insights into its potential as a novel immunotherapy for aggressive and metastatic cancers.